Shots:
- Chinese NMPA CDE has accepted the NDA for opamtistomig (LBL-024) as monotx. for previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)
- The NDA is supported by a registrational study led by Professor Shen Lin of Peking University Cancer Hospital, conducted across 34 sites; the study enrolled 96 pts with EP-NEC and completed enrollment in Aug 2025, with detailed results planned for presentation at a leading international medical congress
- Opamtistomig is a PD-L1/4-1BB bispecific antibody and was granted Priority Review by the CDE on July 10, 2026
Ref: PRNewswire | Image: Leads Biolabs | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
